← Eichor
Study identifier: NCT06283758 Synced from ClinicalTrials.gov · July 29, 2026
● Recruiting

Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension (PARADISE HTN-III)

Condition: Hypertension · Blood Pressure · Cardiovascular Diseases  ·  Sponsor: Suzhou Municipal Hospital

PhaseNA
Planned participants30
Who can joinAll sexes, 18 Years to 65 Years
Healthy volunteersNo

About this study

This seamless two-stage phase II/III clinical trial aims to evaluate the efficacy and safety of a novel focused power ultrasound mediated inferior perirenal adipose tissue modification therapy for essential hypertension. Stage 1 is a phase II, multicenter, open-label, randomized trial to determine the optimal treatment strategy. Stage 2 is a phase III, multicenter, randomized, double-blind trial investigating the efficacy and safety of optimal treatment strategy compared to sham control.

This description comes directly from the study's public registry record.

Talk to the study team

Yanhui Sheng  ·  13851647530  ·  yhsheng@njmu.edu.cn

Yang Hua  ·  13851624359  ·  759150674@qq.com

Always discuss trial participation with your own doctor first.

Locations (4)

The Affiliated Jiangning Hospital of Nanjing Medical UniversityNanjing, Jiangsu, ChinaRecruiting
The first Affiliated Hospital of Nanjing Medical UniversityNanjing, Jiangsu, ChinaRecruiting
Affiliated Hospital of Nantong UniversityNantong, Jiangsu, ChinaRecruiting
Suzhou Municipal HospitalSuzhou, Jiangsu, ChinaRecruiting

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06283758